174 related articles for article (PubMed ID: 25715049)
1. Essential thrombocythaemia.
Double G; Harrison C
Hematology; 2015 Mar; 20(2):119-20. PubMed ID: 25715049
[No Abstract] [Full Text] [Related]
2. Molecular characterisation of triple negative essential thrombocythaemia patients by platelet analysis and targeted sequencing.
Angona A; Fernández-Rodríguez C; Alvarez-Larrán A; Camacho L; Longarón R; Torres E; Pairet S; Besses C; Bellosillo B
Blood Cancer J; 2016 Aug; 6(8):e463. PubMed ID: 27564461
[No Abstract] [Full Text] [Related]
3. Mutation status of essential thrombocythemia and primary myelofibrosis defines clinical outcome.
Asp J; Andréasson B; Hansson U; Wasslavik C; Abelsson J; Johansson P; Palmqvist L
Haematologica; 2016 Apr; 101(4):e129-32. PubMed ID: 26768689
[No Abstract] [Full Text] [Related]
4. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management.
Tefferi A; Barbui T
Am J Hematol; 2015 Feb; 90(2):162-73. PubMed ID: 25611051
[TBL] [Abstract][Full Text] [Related]
5. Distinct molecular abnormalities underlie unique clinical features of essential thrombocythemia in children.
Fu R; Liu D; Cao Z; Zhu S; Li H; Su H; Zhang L; Xue F; Liu X; Zhang X; Cheng T; Yang R; Zhang L
Leukemia; 2016 Mar; 30(3):746-9. PubMed ID: 26118316
[No Abstract] [Full Text] [Related]
6. Interferon alfa therapy in CALR-mutated essential thrombocythemia.
Cassinat B; Verger E; Kiladjian JJ
N Engl J Med; 2014 Jul; 371(2):188-9. PubMed ID: 25006741
[No Abstract] [Full Text] [Related]
7. Contemporary management of essential thrombocythemia in children.
Randi ML; Bertozzi I; Putti MC
Expert Rev Hematol; 2019 May; 12(5):367-373. PubMed ID: 30925843
[TBL] [Abstract][Full Text] [Related]
8. Dysplasia of all granulocyte lineages in myelodysplastic evolution of essential thrombocythemia.
Bain BJ; Garnett C; Deplano S; Naresh K; Kanfer E
Am J Hematol; 2013 May; 88(5):426. PubMed ID: 23460316
[No Abstract] [Full Text] [Related]
9. Long-term follow-up of essential thrombocythemia patients treated with anagrelide: subgroup analysis according to JAK2/CALR/MPL mutational status.
Mela Osorio MJ; Ferrari L; Goette NP; Gutierrez MI; Glembotsky AC; Maldonado AC; Lev PR; Alvarez C; Korin L; Marta RF; Molinas FC; Heller PG
Eur J Haematol; 2016 Apr; 96(4):435-42. PubMed ID: 26119186
[TBL] [Abstract][Full Text] [Related]
10. Distinct driver mutation profiles of childhood and adolescent essential thrombocythemia.
Langabeer SE; Haslam K; McMahon C
Pediatr Blood Cancer; 2015 Jan; 62(1):175-6. PubMed ID: 25132652
[No Abstract] [Full Text] [Related]
11. [Treatment strategy for myeloproliferative neoplasms].
Yoshimoto G; Miyamoto T
Rinsho Ketsueki; 2014 Oct; 55(10):1841-52. PubMed ID: 25297748
[No Abstract] [Full Text] [Related]
12. [Management of patients with essential thrombocythemia].
Ramirez G; García-Sanchez R; Plaza S
Med Clin (Barc); 2013 Mar; 140(6):278-82. PubMed ID: 23177312
[No Abstract] [Full Text] [Related]
13. Anagrelide and the CALR mutation allele burden in essential thrombocythemia.
Atkinson E; Bakri M; Hayat A; Langabeer SE
Exp Oncol; 2018 Jun; 40(2):152-153. PubMed ID: 29949532
[No Abstract] [Full Text] [Related]
14. Significance of thrombocytopenia in patients with primary and postessential thrombocythemia/polycythemia vera myelofibrosis.
Masarova L; Alhuraiji A; Bose P; Daver N; Pemmaraju N; Cortes J; Pierce S; Kantarjian H; Verstovsek S
Eur J Haematol; 2018 Mar; 100(3):257-263. PubMed ID: 29226426
[TBL] [Abstract][Full Text] [Related]
15. Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture.
Tefferi A
Leuk Res; 2012 Dec; 36(12):1481-9. PubMed ID: 22917768
[TBL] [Abstract][Full Text] [Related]
16. Anagrelide and Mutational Status in Essential Thrombocythemia.
Iurlo A; Cattaneo D; Orofino N; Bucelli C; Fabris S; Cortelezzi A
BioDrugs; 2016 Jun; 30(3):219-23. PubMed ID: 27041108
[TBL] [Abstract][Full Text] [Related]
17. Pathogenesis and management of essential thrombocythemia.
Beer PA; Green AR
Hematology Am Soc Hematol Educ Program; 2009; ():621-8. PubMed ID: 20008247
[TBL] [Abstract][Full Text] [Related]
18. It is time to change thrombosis risk assessment for PV and ET?
Passamonti F; Caramazza D; Mora B; Casalone R; Maffioli M
Best Pract Res Clin Haematol; 2014 Jun; 27(2):121-7. PubMed ID: 25189723
[TBL] [Abstract][Full Text] [Related]
19. Thrombopoietin Measurement as a Key Component in the Evaluation of Pediatric Thrombocytosis.
Nelson ND; Marcogliese A; Bergstrom K; Scheurer M; Mahoney D; Bertuch AA
Pediatr Blood Cancer; 2016 Aug; 63(8):1484-7. PubMed ID: 27100794
[TBL] [Abstract][Full Text] [Related]
20. Essential thrombocythemia: diagnosis and treatment, with special emphasis on the use of anagrelide.
Andersson BS
Hematology; 2002 Jun; 7(3):173-7. PubMed ID: 12243981
[No Abstract] [Full Text] [Related]
[Next] [New Search]